Biotalys, a company that develops protein-based biocontrols for sustainable crop protection, has been granted patents for its first biofungicide, EVOCA, by the European Patent Office and the United States Patent and Trademark Office.
The patents, which were granted following a thorough examination of the company’s applications, protect the active ingredient of EVOCA and provide Biotalys with the exclusivity needed to support its commercial partners in producing or distributing the product in Europe and the United States.
EVOCA is a novel protein-based biofungicide that has earned an entirely new resistance classification from the Fungicide Resistance Action Committee. The product is designed to help control fungal disease in fruits and vegetables, and has demonstrated strong performance in trials across multiple regions, climates, soil types, production types, pathogen pressure and crops.
Biotalys has also requested patent protection for the active ingredient of EVOCA in countries around the globe, including Argentina, Brazil, and South Africa. The company already holds various patents worldwide on different elements of its technology and is continually building its intellectual property protection for its products, formulations, and processes.
EVOCA is currently under review by the U.S. Environmental Protection Agency and the Dutch College CTGB in the European Union for regulatory approval. The company plans to launch EVOCA NG, a commercial fungicide from its AGROBODY technology platform, once EVOCA is approved.
The patent grants for EVOCA will pave the way for Biotalys’ first commercial fungicide from its AGROBODY technology platform.
